Cost-effectiveness of Pola+R-CHP therapy for diffuse large B-cell lymphoma

JRCT ID: jRCT1031230035

Registered date:17/04/2023

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Diffuse large B-cell lymphoma
• Date of first enrollment: 17/04/2023
• Target sample size: 879
• Study type: Observational

Outcome(s)

• Primary Outcome: Incremental cost-effectiveness ratio (ICER) for Pola+R-CHP compared to R-CHOP

Secondary Outcome

1) Expected cost and effectiveness per patient in Pola + R-CHP therapy
2) Expected cost and effectiveness per patient in R-CHOP therapy

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Both
• Include criteria: patients with previously untreated Diffuse large B-cell lymphoma
• Exclude criteria: none

Related Information

• Primary Sponsor: Mizuoka Takashi
• Secondary Sponsor: Nishi Kazuhiko